A blood test that can catch stomach, liver, and nasopharyngeal cancers.
Cancers that, in most of Asia, have zero routine screening programs.
Sit with that for a second.
Because that gap has quietly killed millions.
Now a Vietnam-founded biotech called Gene Solutions says it's closing that gap — and it just brought the receipts to ASCO Breakthrough 2026 in Singapore.
One blood draw.
AI reads it.
10 cancer types flagged.
👉 It hunts for cancer signals hiding in your cell-free DNA — the tiny fragments tumors leak into your bloodstream.
No biopsy. No scan. Just blood.
84,145 asymptomatic people tested.
Across Singapore, Thailand, Indonesia, the Philippines, Malaysia, and Vietnam.
The largest real-world multi-cancer detection cohort ever reported from any Asian population.
Not a lab study. Not mice. Real people, real clinics, real follow-up.
In a deeper look at 22,597 of them — tracked for over a year — the results held up against an earlier validation study.
The test didn't just find the "usual" cancers Western tests are built for.
It found the ones Asia actually dies from.
None of these have a standard screening test.
Until now, maybe.
As lead researcher Dr. Dang Nguyen put it: Asia's cancer landscape is fundamentally different from where other blood tests were built and validated.
This one wasn't imported. It was built for the region, on the region.
In May 2026, the U.S. FDA granted SPOT-MAS 10 Breakthrough Device Designation.
That's not approval.
But it's the FDA saying: keep going, this is worth fast-tracking.
And Bloomberg reports Gene Solutions is now eyeing a Hong Kong IPO to fuel global expansion.
For decades, medical innovation has flowed one direction — West to East.
This one's flowing the other way.
An Asia-built test, validated on Asian patients, now being watched by American regulators and global investors.
That reversal alone is the headline.
That's all for now!
